BioCrossroads is proud to announce that GeniPhys has been named the recipient of the inaugural BioCrossroads Life Sciences Innovation Team of the Year Award at the 2025 TechPoint Mira Awards, held this evening at the Palladium in Carmel.

Presented for the first time at Indiana’s premier technology and innovation awards event, this new category honors life sciences teams in Indiana that have demonstrated groundbreaking advancements in research, development, and application to improve patient outcomes.

GeniPhys, based in Indianapolis, was recognized for its innovative work in developing biomaterials that enhance tissue regeneration and wound healing. Their dedication to pushing the boundaries of life sciences exemplifies the spirit of innovation that strengthens Indiana’s leadership in the health, biotechnology, medical device, and pharmaceutical sectors.

“BioCrossroads is thrilled to recognize GeniPhys with our inaugural innovation award,” said Vince Wong, BioCrossroads’ President & CEO. “The exceptional quality of the finalists highlights the depth of talent and innovation in Indiana’s life sciences sector. GeniPhys’ novel collagen-based biomaterial platform has great potential to address a critical unmet need in regenerative medicine, so we are pleased to highlight their promising innovation.”

We also extend our congratulations to all our finalists:

Each of these organizations represents the ingenuity, collaboration, and forward-thinking spirit that make Indiana a global leader in life sciences.

As an initiative of the Central Indiana Corporate Partnership (CICP), BioCrossroads is dedicated to advancing Indiana’s life sciences sector by supporting the innovators, organizations, and collaborations that drive growth, discovery, and improved patient outcomes.

Learn more about the Mira Awards and other 2025 winners here.



AnalytiXIN creates new Indiana healthcare-based consortium to advance data-driven clinical research and improve health outcomes

New shared platform will use consented health data to facilitate life sciences research, advance healthcare, and to engage patients via precision medicine

INDIANAPOLIS (January 21, 2025) – AnalytiXIN today announced the launch of a new consortium to help healthcare organizations across Indiana better identify and access comprehensive, consented clinical and genomic health data. It is a continued investment to improve patient outcomes and drive efficiencies to accelerate clinical research. Access to these diverse datasets will allow researchers to quickly develop and conduct more accurate and personalized studies, enabling more effective healthcare interventions, further establishing Indiana as a leader in health sciences data analytics.

Several leading Indiana-based healthcare companies, including Eli Lilly and Company (“Lilly”), Indiana University (IU) Health, IU School of Medicine, and the Indiana Health Information Exchange (IHIE) have pledged unprecedented commitment to this collaboration.

“We’re excited to work with our AnalytiXIN consortium partners to harness the power of data analytics, with the aim of advancing scientific research and improving health outcomes,” said David A. Ricks, Lilly chair and CEO. “Accurate, comprehensive data will provide our researchers with important new insights that will enhance clinical trial design and enrollment and accelerate the development of innovative new medicines for people here in Indiana and around the world.”

The consortium will serve a broad range of stakeholders, including life sciences researchers, healthcare providers, and data scientists, fostering collaboration to accelerate data-driven clinical research. By bringing together experts in precision medicine, genomics, and data analytics, the consortium will drive innovative research efforts. It will prioritize improving health outcomes, with a focus on cardio-metabolic diseases, neurodegenerative conditions, and other critical health challenges impacting Hoosiers.

“The AnalytiXIN consortium’s success depends on Hoosiers joining the Indiana Biobank. Their involvement, along with our partners’ expertise, helps us understand treatments tailored to each person’s genetics,” said Dennis Murphy, president and CEO of IU Health. “With over 60,000 Hoosiers already participating, more people joining will help us prevent and treat diseases, making Indiana one of the healthiest states in the nation.”

“The AnalytiXIN consortium is an exciting opportunity to harness the vast resources held within the Indiana Biobank here at the IU School of Medicine, coupled with the depth of data contained in IU Health’s electronic medical records, to help accelerate the discovery of new therapies,” said Jay L. Hess, MD, PhD, MHSA, dean of the IU School of Medicine and IU’s executive vice president for university clinical affairs. “The impact that this collaboration could have on the health of Hoosiers across the state is immeasurable. The School of Medicine is thrilled to be a partner in this groundbreaking effort.”

AnalytiXIN is a strategic program run by the Central Indiana Corporate Partnership (CICP) and is designed to bolster the economic vitality and drive sustained innovation in Indiana by advancing the integration of strategic technologies—artificial intelligence, machine learning, and data analytics—in the life sciences and manufacturing industries, both significant drivers of the state’s economic, social and physical wellbeing. It is funded with support from Lilly Endowment Inc.

“By leveraging this unique life sciences health data asset, we’re empowering our partners like Lilly, IU Health, and the IU School of Medicine to accelerate innovation and drive breakthroughs faster and more effectively than ever,” said Melina Kennedy, CEO of the Central Indiana Corporate Partnership. “We invite life sciences industry leaders, health systems, and universities to join us in harnessing this asset to further advance Indiana’s leadership in healthcare and life sciences.”

About AnalytiXIN

AnalytiXIN was established through a Lilly Endowment Inc. grant to the Central Indiana Corporate Partnership to develop a digital community, including a place-focused collaboration hub in Indianapolis that will strengthen connections and encourage engagement of academic data science R&D talent with their industry peers to drive sustained innovation within Indiana. The project is intended to grow and enable the digital ecosystem and drive sustained innovation within the State. The emphasis is on life sciences and manufacturing – two of Indiana’s most important and prolific economic drivers. To learn more, visit www.analytixindiana.com.

About Central Indiana Corporate Partnership (CICP)

The Central Indiana Corporate Partnership (CICP) was formed in 1999 to bring together the chief executives of the region’s prominent corporations, foundations and universities in a strategic and collaborative effort dedicated to Indiana’s continued prosperity and growth. To advance this mission, CICP sponsors five key talent and industry sector initiatives, AgriNovus Indiana, Ascend Indiana, BioCrossroads, Conexus Indiana, and TechPoint, each of which addresses challenges and opportunities unique to its respective area: agbiosciences, talent and workforce development, life sciences, advanced manufacturing and logistics, advanced energy technology and transportation and technology. To learn more, visit www.cicpindiana.com.

###

INDIANAPOLIS (December 2024) – The Central Indiana Corporate Partnership (CICP), alongside its branded initiatives BioCrossroads, Conexus Indiana and TechPoint, announces the appointment of three senior leaders who will play pivotal roles in shaping the future of Indiana’s life sciences, advanced manufacturing and logistics and technology sectors.

Douglas Kiehl, Patrick “PJ” McGrew and Casey Osterkamp joined BioCrossroads, Conexus Indiana and TechPoint, respectively, in senior leadership roles on December 10.

“As we ensure the strength of Indiana’s advanced industries, these strategic hires underscore our commitment to building a thriving, innovative economy,” said Melina Kennedy, CEO of the Central Indiana Corporate Partnership. “Doug, PJ and Casey each bring a depth of expertise that will help us tackle workforce challenges, advance technological adoption and foster cross-sector collaboration. Together, they will elevate our efforts to position Indiana as a global leader in innovation and talent development.”

BioCrossroads adds SVP of Workforce Development and Chief Technology Strategist
Douglas Kiehl, BioCrossroads’ new senior vice president of Workforce Development and Chief Technology Strategist brings over three decades of experience at Eli Lilly and Company, serving most recently as senior director leading the Disruptive/Transformative Technologies Team (DT3) and the Digital Twin Center of Excellence. His work focused on digital transformation, automation, extractables/leachables and next-generation bioprocessing.

In his new role, Kiehl will leverage his experience driving multi-stakeholder initiatives to lead BioCrossroads’ workforce development initiatives and contribute to its 10-year strategy to build a skilled talent pool for Indiana’s life sciences and healthcare industries.

“Doug’s extensive experience and passion for forging the adoption of next-generation technologies makes him a tremendous addition to our team,” said Vince Wong, CEO of BioCrossroads. “His leadership will be key in driving our strategic efforts to enhance Indiana’s life sciences and healthcare sectors. By cultivating a skilled workforce and championing adoption of new technologies, Doug will help prepare our workforce for the future and ensure that BioCrossroads continues to support the growth and success of Indiana’s life sciences and healthcare communities.”

Conexus Indiana names SVP of Talent Strategy and Programming
Patrick “PJ” McGrew joins Conexus Indiana as senior vice president of Talent Strategy and Programming. McGrew brings nearly a decade of state government experience, including serving as the inaugural executive director of the Governor’s Workforce Cabinet, where he gained national recognition for his efforts to bridge the education-to-workforce pipeline. His career also includes ten years as a high school teacher in diverse educational settings, with a passion for fostering economic mobility and career exploration for students.

In his new role, McGrew will focus on developing innovative workforce solutions to meet the evolving needs of Indiana’s advanced manufacturing and logistics sectors, further positioning the state as a leader in these industries.

“PJ’s wealth of experience in education and workforce development will be instrumental in addressing the talent challenges facing Indiana’s advanced manufacturing and logistics sectors,” said Fred Cartwright, president and CEO of Conexus Indiana. “His proven ability to bridge the gap between education and industry makes him a great fit for Conexus and we’re excited to have his leadership as we continue to develop forward-thinking talent strategies for our state.”

TechPoint appoints SVP and COO
Casey Osterkamp joins TechPoint as senior vice president and Chief Operating Officer (COO) with a wealth of experience in organizational leadership and talent strategy, most recently as a project consultant at 17a, COO at Herron Classical Schools and concurrently as vice president of Operations at Herron High School.

She is experienced in talent consulting and organizational leadership. In the past, she was the Director of Personnel for the State of Missouri and Director at the Assessment Resource Center. She’s also held consulting positions with IBM and the Harvard Kennedy School of Government. Osterkamp also served as a Surface Warfare Officer in the U.S. Navy.

Osterkamp will work closely with TechPoint’s CEO to lead overall people and operations, to drive more intentional cross-initiative collaborations, and to ensure quality delivery of TechPoint programs and partner enablement strategies.

“We are thrilled to have Casey join our team,” said TechPoint CEO Ting Gootee. “She has a depth of experience that will support TechPoint’s goals and vision to champion and strengthen Indiana’s tech sector.”

These new leaders reflect the CICP’s commitment to fostering innovation, collaboration and workforce development across Indiana’s key economic sectors.

###
About CICP

The Central Indiana Corporate Partnership (CICP) was formed in 1999 to bring together the chief executives of the region’s prominent corporations, foundations and universities in a strategic and collaborative effort dedicated to Indiana’s continued prosperity and growth. To advance this mission, CICP sponsors five key talent and industry sector initiatives, AgriNovus Indiana, Ascend Indiana, BioCrossroads, Conexus Indiana and TechPoint, each of which addresses challenges and opportunities unique to its respective area: agbiosciences, talent and workforce development, life sciences, advanced manufacturing and logistics, and technology. To learn more about CICP, visit www.cicpindiana.com.

About BioCrossroads

Established as a catalyst to advance, grow, and invest in Indiana’s life sciences sector, BioCrossroads is a branded initiative of the Central Indiana Corporate Partnership. It supports the region’s existing enterprises and encourages new business development. The initiative fosters public-private collaboration by uniting a diverse range of academic, industry, and philanthropic stakeholders, all collectively focused on advancing Indiana’s life sciences sector. Committed to supporting the growth of capital investments and talent development, BioCrossroads provides support to both existing and new life sciences enterprises, including the Indiana Health Information Exchange, OrthoWorx, and the Indiana Biosciences Research Institute. BioCrossroads champions the advancement of cutting-edge research and development, plays a crucial role in building and nurturing a robust talent pipeline, and is dedicated to establishing Indiana as a thriving hub for life sciences manufacturing. To learn more about BioCrossroads, visit crossroadshealthventures.com.

About Conexus Indiana
Conexus Indiana, a branded initiative of the Central Indiana Corporate Partnership, is dedicated to advancing the Hoosier State’s position as a global leader in advanced manufacturing and logistics. Working closely with industry, academia, and government partners, Conexus Indiana drives workforce development, economic growth, and innovation across the state. For more information, please visit ConexusIndiana.com.

About TechPoint
TechPoint is the Central Indiana Corporate Partnership’s industry-led growth initiative for Indiana’s digital innovation economy and overall tech ecosystem. The team is focused on working with public, private and industry partners to expand tech talent pipeline, enhance resource connectivity for enterprise organizations and startups alike, and elevate the industry by activating the community and amplifying stories of success. For more information, please visit www.techpoint.org.

A Glimpse into the Future of Nuclear Medicine

Our FrameWORX series this year has been a fascinating journey through the pillars of our strategic life sciences plan for Indiana. Our final event of the year – held earlier this month at the Indiana Biosciences Research Institute – can feel like a big gulp of science. But no area captures Indiana’s life sciences growth like nuclear medicine and radiopharmaceuticals.

Indiana leads the nation in conventional pharmaceutical exports, and at least 14 life sciences companies today are developing and manufacturing radiopharmaceuticals – propped by our state’s central location and logistics expertise. Decades of life sciences leadership are complemented by the logistics required to produce treatments and diagnostics that leave little room for shelf life. Radioactive materials degrade quickly, and each dose must reach the intended patient within 3 to 5 days from production. Indiana’s FedEx hub, the second largest in the world, is a major advantage – as is the fact Central Indiana is a 12-hour drive from approximately half the U.S.

Indiana is on the leading edge of a booming technology. Nuclear medicine is a $6 billion industry in the U.S. and is expected to triple in the next 7 years. Heartland BioWorks, designated a regional technology and innovation hub by the federal Economic Development Administration, has established BioTrain, an institute designed to prepare talent for entry-level biomanufacturing roles. BioTrain will be located at the 16 Tech Innovation District. And just north of Indianapolis, Purdue has the nation’s largest nuclear medicine pharmacy program in the country.

As demonstrated at our FrameWORX, radiopharmaceuticals are used in nuclear medicine imaging and procedures – particularly for prostate and other cancers. They are administered systemically, but their biomolecular properties cause them to localize in specific tissues. Years ago, doctor might use a sledgehammer approach to treatment – in other words, diagnose and treat a large swath of the body to address diseases that were challenging to pinpoint. Radiopharmaceuticals are more like using an arrow and bull’s eye. Precision leads to less invasiveness and more precise treatments for patients.

Researchers and business leaders from IU School of Medicine, Purdue, life sciences companies, and the patient advocacy world drove a robust discussion about the future of radiopharmaceuticals. Perhaps no one said it better than Geoff Towle, a vice president and senior general manager at Novartis. Geoff joined us from his New Jersey headquarters because his company has built a large radiopharmaceutical manufacturing plant in Indianapolis.

“This feels like reimagining medicine,” he said. “Nuclear medicine is incredibly effective and exquisitely targeted. Patients are waiting for this and that’s what we need to focus on.”

Thank you to our December FrameWORX Presenting Sponsor

New report highlights Indiana’s thriving bioscience sector, driving job growth, investment, and cutting-edge research

The latest report from BIO, “The U.S. Bioscience Economy: Driving Economic Growth and Opportunities in States and Regions,” presents a comprehensive analysis of the bioscience industry’s growing impact on the U.S. economy, with Indiana standing out as a significant contributor. Biosciences continue to be a key driver of innovation, contributing significantly to employment, economic growth, and quality of life improvements across the country. The report underscores how the bioscience sector, with its diverse subsectors including biotechnology research, biopharmaceuticals, and medical devices, plays an instrumental role in fostering regional economic development and competitiveness.

Dave Ricks, CEO of Eli Lilly and Company, Recognized as 2024 Watanabe Life Sciences Champion for Pioneering Leadership in Indiana’s Life Sciences Industry

INDIANAPOLIS (Nov. 7, 2024) — BioCrossroads has named Dave Ricks, CEO of Eli Lilly and Company, as the recipient of the 2024 August M. Watanabe Life Sciences Champion of the Year Award. The prestigious honor was presented at the annual BioCrossroads Life Sciences Summit, recognizing Ricks’ significant contributions to Indiana’s life sciences sector and his global impact on healthcare innovation.

Under Ricks’ visionary leadership, Lilly has strategically invested billions into research and development to tackle some of the most challenging diseases with high unmet need. This strategy and dogged commitment to innovation has propelled Lilly to the forefront of developing innovative treatments in areas such as obesity, diabetes, oncology, immunology, and neurodegenerative diseases including Alzheimer’s, Parkinson’s, and ALS. Lilly played a key role in bringing patients vital COVID-19 therapies. In 2024 alone, Lilly has committed over $9B in capital investments in Indiana, which will undoubtably have a transformative impact on the state for generations to come.

“We are thrilled to honor Dave Ricks with the August M. Watanabe Life Sciences Champion of the Year Award,” said Vince Wong, President and CEO of BioCrossroads. “His visionary leadership and strategic focus on innovation at Lilly have not only advanced the life sciences industry in Indiana but have also made a profound global impact on healthcare. Dave exemplifies the spirit of discovery and collaboration that this award represents.”

The August M. Watanabe Life Sciences Champion of the Year Award, presented by BioCrossroads, was established in honor of BioCrossroads’ late chairman, Dr. August “Gus” M. Watanabe, an esteemed and transformative figure in Indiana’s life sciences community.

The award celebrates those who have significantly advanced the development, education, and promotion of Indiana’s life sciences and healthcare sector; personify the emerging face of the industry; and drive innovative developments that have both local and global impacts. Past distinguished honorees have come from diverse backgrounds, including entrepreneurial ventures, research, corporate leadership, medical practice, academia, and philanthropy.

Dr. Watanabe’s passion and impact on Indiana’s life sciences community were transformative and enduring. Beyond his professional accomplishments, his caring and nurturing spirit continues to inspire the many people he touched throughout his career. Each recipient of this award embodies Dr. Watanabe’s legacy, contributing profoundly to the state’s growth in life sciences through their dedication and cumulative efforts.

Previous August M. Watanabe Life Sciences Champion of the Year award winners include:

Indiana For the Bold:
Transforming Indiana’s Life Sciences Sector with Vince Wong

BioCrossroads President and CEO Vince Wong was recently a guest on the Indiana for the Bold podcast, where he joined host Salena Scardina to share his journey and the impactful work happening in Indiana’s life sciences sector.

During the episode, Vince discusses his Indiana roots, educational background, and career trajectory, including leadership roles at Telamon Corporation and Roche Diagnostics. Now leading BioCrossroads, he dives into the organization’s focus on driving innovation, advancing manufacturing, developing the workforce, and fostering collaboration across the state.

He also highlights Indiana’s leadership in biotech patenting, securing NIH funding, and its emergence as a hub for GLP-1 obesity therapies. Additionally, Vince covers BioCrossroads’ new mentorship program, investments in biotech manufacturing, and Warsaw’s thriving medical and orthopedic manufacturing industry.

BioCrossroads Announces Additions and Changes to the Board of Directors

INDIANAPOLIS (September 3, 2024) – BioCrossroads, the Central Indiana Corporate Partnership initiative established as a catalyst to advance, grow, and invest in Indiana’s life sciences sector, is pleased to announce seven new appointments to its Board of Directors and key elevations within its current Board members to the Executive Committee. These strategic additions and transitions are closely aligned with BioCrossroads’ efforts to advance the ambitious statewide 10-year industry strategy it released in January, aimed at advancing research and innovation, manufacturing ecosystems, and workforce development within Indiana’s life sciences sector. In furtherance of these strategic focus areas, BioCrossroads is pleased to announce the elevation of Cathy Langham, President and CEO of Langham Logistics, and Alan Palkowitz, PhD, President and CEO of the Indiana Bioscience Research Institute, to the Executive Committee. Langham, a Board member since April 2023, is a Sagamore of the Wabash recipient, a CICP board member, Indiana University Trustee, and community leader, bringing extensive entrepreneurship experience and community connectivity to her new role. Palkowitz, who joined the Board in 2021, brings over three decades of expertise in drug discovery and development, with extensive leadership experience at IBRI, Indiana University School of Medicine, and Eli Lilly and Company. Their elevated leadership roles will be crucial in steering BioCrossroads toward new initiatives and further strengthening Indiana’s life sciences ecosystem. “These leadership changes are not only a reflection of our commitment to fostering growth and innovation within Indiana’s life sciences sector, but also help ensure we have the right vision and expertise as we work to fulfill our ambitious 10-year plan,” said BioCrossroads’ Board Chair Dan Peterson, VP of Industry and Government Affairs at Cook Medical. “Elevating seasoned leaders like Cathy Langham and Alan Palkowitz to our Executive Committee reinforces our capacity to drive forward initiatives that will solidify Indiana’s position as a global life sciences leader.” In addition to these leadership elevations, BioCrossroads welcomes seven new members to its Board of Directors:
  • Ryan Baehl, Global Head of Operations for Labcorp Central Lab, replaces Stacey Yount on the Board. With nearly 20 years of experience in clinical research and laboratory operations, Baehl’s expertise will be crucial as BioCrossroads works toward fueling innovation within Indiana’s life sciences sector.
  • Dr. Matt Connell, Vice President of Healthcare at Ivy Tech, marks Ivy Tech’s first representation on the Board. Connell’s distinguished career in healthcare education and administration has been instrumental in shaping programs that align educational outcomes with industry needs, which will be helpful in guiding BioCrossroads’ emerging talent and workforce development initiatives.
  • Dr. Daniel Golden, Vice President and Global Head of Research, Discovery, and Breakthrough Innovation at Elanco Animal Health, joins the Board, succeeding Marcela Kirberger. Golden’s leadership in scientific discovery and innovation at Elanco will support BioCrossroads’ efforts to advance research initiatives in Indiana.
  • Dr. David Ingram, IU Health’s System Chief Medical Executive, succeeds Ron Stiver on the Board. Ingram’s vast experience in research and clinical leadership and his commitment to improving healthcare delivery will provide invaluable insights as BioCrossroads continues its mission to enhance Indiana’s life sciences industry.
  • Jim Lancaster, President of Recon and Global Headquarters Executive Director for Zimmer Biomet, brings decades of leadership in the orthopedics industry, including significant experience at Zimmer Biomet. Lancaster’s deep understanding of the medical device sector will be instrumental in aligning BioCrossroads’ efforts with the needs of this critical industry.
  • Cory Lewis, President and CEO of INCOG BioPharma Services, joins the Board with extensive experience in pharmaceutical manufacturing and entrepreneurship. Lewis’ expertise will be crucial as BioCrossroads works to expand life sciences manufacturing and foster entrepreneurship in the state.
  • Ron Penczek, Chief Accounting Officer at Elevance Health, succeeds Bryony Winn as Elevance Health’s representative on the Board. With over 20 years of executive leadership at one of the nation’s largest payor organizations, Penczek will bring valuable strategic insights and functional expertise to BioCrossroads, as the organization seeks to advance Indiana’s life sciences sector.
“As we welcome these new industry leaders to our Executive Committee and Board, we extend our deepest gratitude to the departing members whose contributions have been instrumental in our success,” said BioCrossroads’ President and CEO, Vince Wong. “Each new board member brings expertise that complements our strategic goals, enhancing our capacity to foster innovation, expand life sciences manufacturing, nurture workforce development, and elevate Indiana’s profile as a leader in life sciences. Ultimately, these efforts are focused to drive economic growth and maximize Indiana’s enormous potential to make a positive impact on human health. Their diverse experiences and insights will play a critical role in furthering our objectives and contributing to the sector’s overall success.”

BioCrossroads Announces the 2024 Indiana Life Sciences Summit, “Transforming Healthcare: Indiana’s Role in Revolutionizing Diabetes and Obesity Management”

INDIANAPOLIS (July 15, 2024) – BioCrossroads is excited to announce the annual Indiana Life Sciences Summit, scheduled for November 7, 2024, at the Biltwell Event Center in Indianapolis. The Summit will focus on “Transforming Healthcare: Indiana’s Role in Revolutionizing Diabetes and Obesity Management,” highlighting Indiana’s significant impact on healthcare, particularly in the development of GLP-1 therapies, which are revolutionizing diabetes and obesity care, and the opportunities that lie ahead for continued advancement of future therapies. GLP-1 therapies, developed and delivered through the relentless efforts of Indiana’s researchers and companies, have emerged as vital tools in managing obesity and diabetes, offering new hope to millions worldwide.

Nationwide, more than 38 million[1] Americans are living with diabetes, with obesity being linked to as many as 53 percent of new cases of type 2 diabetes each year.[2] In Indiana, more than 12% of the adult population is living with diabetes, with an estimated 31,200 more adults expected to be diagnosed every year,[3] and Indiana’s obesity rate is higher than the national average and has been increasing steadily over the past 20 years. As of 2021, 36.3 percent, more than two-thirds of adults in Indiana were obese and 33.3% were overweight. This places Indiana 12th in the nation for obesity[4]—making the demand for effective solutions even more critical.

“Indiana’s contributions to GLP-1 therapies are also setting new standards in the global fight against obesity and metabolic diseases,” said Vince Wong, CEO of BioCrossroads. “The 2024 Indiana Life Sciences Summit is a compelling platform to highlight the pivotal role Indiana has played in bringing transformative innovation to address some of the most challenging unmet needs in healthcare and to gain insights into future developments that will benefit patients, not only in Indiana, but throughout the world. By bringing together industry leaders, researchers, and patients, we aim to foster collaboration and inspire further breakthroughs in diabetes and obesity care.”

A highlight of the event will be the presentation of the prestigious August M. Watanabe Life Sciences Champion of the Year Award, honoring exceptional contributions to life sciences in Indiana. Named in memory of Dr. August “Gus” Watanabe, a visionary in the industry, this award recognizes outstanding achievements and significant contributions in life sciences.

Secure your front row seat for this impactful discussion. Register now and join BioCrossroads at the 2024 Indiana Life Sciences Summit. For more information and to register, please visit BioCrossroads.

Transforming Healthcare, Indiana’s Role in Revolutionizing Diabetes and Obesity Management

Save the Date: November 7, 2024
Location: Biltwell Event Center, Indianapolis
Time: 9:00 AM – 3:30 PM

Register Here

 

About BioCrossroads
Established as a catalyst to advance, grow, and invest in Indiana’s life sciences sector, BioCrossroads is an initiative of the Central Indiana Corporate Partnership (CICP). It supports the region’s existing enterprises and encourages new business development. The initiative fosters public-private collaboration by uniting a diverse range of academic, industry, and philanthropic stakeholders, all collectively focused on advancing Indiana’s life sciences sector. Committed to supporting the growth of capital investments and talent development, BioCrossroads provides support to both existing and new life sciences enterprises, including the Indiana Health Information Exchange, OrthoWorx, and the Indiana Biosciences Research Institute. BioCrossroads champions the advancement of cutting-edge research and development, plays a crucial role in building and nurturing a robust talent pipeline, and is dedicated to establishing Indiana as a thriving hub for life sciences manufacturing. To learn more about BioCrossroads, visit crossroadshealthventures.com.

[1] CDC National Diabetes Statistics Report [2] American Heart Association Obesity and Diabetes Link [3] American Diabetes Association. The Burden of Diabetes in Indiana [4] Richard M. Fairbanks Foundation, Indiana’s Obesity Epidemic

Leading by Example: Life Sciences Manufacturing in Indiana

From Development to Delivery: Indiana’s Edge in Life Sciences Manufacturing

Indiana’s heritage in life sciences manufacturing dates back more than 100 years. In 1923, Eli Lilly and Company became the first-ever organization to mass produce insulin for patients living with diabetes—helping change the trajectory of countless lives around the world.

Indiana stands as a leader in manufacturing, drawing envy from states nationwide. Our state leads the nation in pharmaceutical exports and holds the second place in exporting life sciences products. The path ahead is marked by significant opportunities, such as Lilly’s $9 billion manufacturing pledge in Boone County, our pioneering role in radiopharmaceutical manufacturing, and Ivy Tech’s recent unveiling of a 4,000-square-foot Biopharma Science and Technology Lab. These developments position Indiana at the forefront of potential growth, provided we maintain our focus and continue to drive forward with unwavering commitment.

Our latest FrameWORX discussion on manufacturing was held before an overflow crowd on June 20 in the Fishers Life Sciences and Innovation District, another Central Indiana community that is booming with life sciences jobs.

Our host, INCOG BioPharma Services, has been around less than five years and recently received FDA approval for a new sterile injectable facility, positioning the company as an emerging contract manufacturing leader. Our other guests – representing diverse organizations such as Lilly, Purdue, IEDC, Langham Logistics, and Stevanato Group – agreed that Indiana’s leadership was underscored by the diverse and engaged crowd that showed up to learn and discuss how we can sharpen our skills.

There’s no finish line when it comes to life sciences manufacturing. Like the rest of the world, technology and customer needs are moving fast: AI, digital twins, and continuous manufacturing are evolving quickly, and Hoosier companies must keep up. Other states want what we have here – but we must keep the conversation going.

Thank you to our expert panelists:

Thank you to our series title sponsors, Faegre Drinker, as well as our presenting sponsors and hosts for this event, INCOG BioPharma Services.

Join us on September 18 for our next FrameWORX, Fueling the Future: Indiana’s Life Sciences Workforce.